Advances in cancer immunotherapy based on chimeric antigen receptor
LI Ling
MA Jianbo
Abstract：Recently,application of chimeric antigen receptor ( CAR) modified T cells in the treatment of lymphoma, leukemia, brain glioma, melanoma, lung cancer, prostate cancer, panc￣reatic cancer and ovarian cancer has made very exciting progress. CAR is a kind of genetically engi￣neered receptor,the common form of these molecules consists of extracellular antigen recognition re￣gion,spacer,transmembrane domain ( TM ) and intracellular endodomain, the antigen recognition region generally is single￣chain variable fragments ( scFv) derived from monoclonal antibodies which can recognize target antigen without MHC restriction, and the intracellular endodomain generally is comprised of CD3 zeta and co￣stimulating molecules. This kind of unique design and strong anti￣tumor effect make the CAR￣T more and more widely used. In this review, we highlight recent ad￣vances of CAR￣T in clinical applications, discovered problems and possible solving strategies in cancer therapy.
Keywords：Chimeric antigen receptor( CAR)T cellTumorImmunotherapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 97-104 )